Neuropathy Treatment: The Rebuild Protocol™ Complete Guide
Table of Contents
- What Neuropathy Treatment Is
- Root Cause Categories: Why Diagnosis Comes First
- Types of Neuropathy: Diabetic, Peripheral, Chemotherapy-Induced, Small Fiber, Idiopathic, and Compressive
- The Rebuild Neuropathy Protocol™: 6 Modalities Explained
- Modality 1: LightForce® XLi Class IV Laser (Photobiomodulation)
- Modality 2: Chattanooga Intelect RPW 2 Shockwave Therapy
- Modality 3: IV Infusions (B12, ALA, NAD+)
- Modality 4: Hormonal Correction (HRT/TRT for Hormone-Driven Neuropathy)
- Modality 5: Metabolic Optimization (Semaglutide, Tirzepatide, Peptides)
- Modality 6: Mechanical Decompression (Knee on Trac, Antalgic-Trac®)
- How Most Neuropathy Clinics Fail Their Patients
- Who Is a Candidate for the Rebuild Neuropathy Protocol™
- What to Expect: Evaluation Through Treatment
- Results and Realistic Expectations
- Costs: What the Protocol Includes
- Is the Rebuild Neuropathy Protocol™ Right for Your Type of Neuropathy?
- Frequently Asked Questions
- When Neuropathy Has Progressed Beyond Conservative Intervention
What Neuropathy Treatment Is
Neuropathy treatment is a multi-modal medical protocol that addresses peripheral nerve damage by first identifying the root cause, whether diabetic, peripheral, compressive, metabolic, or chemotherapy-induced, and then applying a targeted combination of interventions designed to reduce neuroinflammation, restore blood flow, and support nerve regeneration.
This definition sets the clinical standard that drives every decision in the Rebuild Neuropathy Protocol™. Neuropathy is not a single disease. It is a symptom complex, a constellation of burning, tingling, numbness, shooting pain, and loss of sensation that can arise from a dozen different biological causes. Treating neuropathy without identifying the root cause is the single biggest reason patients cycle through treatments for years without meaningful improvement.
Peripheral neuropathy affects an estimated 20 million Americans. It is one of the most undertreated and poorly managed conditions in conventional medicine. Neurologists confirm the diagnosis. They prescribe medications that address pain signals, primarily gabapentin, pregabalin, and amitriptyline, without addressing the nerve damage driving those signals. The damage progresses. The medications fail to keep pace. Patients arrive at Rebuild Regen having been on three or four medications for years, still in pain, and never once told what was actually causing their neuropathy.
The Rebuild Neuropathy Protocol™ starts where it should always have started: with the question of why the nerves are damaged in the first place.
Root Cause Categories: Why Diagnosis Comes First
The Rebuild Neuropathy Protocol™ is organized around root cause identification. Before any treatment modality is applied, the underlying driver of neuropathy is established through clinical history, physical examination, and targeted laboratory testing.
The 5 Root Cause Categories
1. Diabetic and Pre-Diabetic (Metabolic Root Cause) Diabetes is the most common cause of peripheral neuropathy in the United States. Chronic elevated blood glucose produces advanced glycation end products (AGEs) that damage the myelin sheath and axonal structure of peripheral nerves. Simultaneously, diabetic microangiopathy (small blood vessel disease) reduces the blood supply to nerve tissue, compounding the damage.
Critical distinction: neuropathy often develops in pre-diabetes, before a formal diabetes diagnosis is made. HbA1c between 5.7 and 6.4 percent is sufficient to initiate the nerve-damaging metabolic environment. Patients with pre-diabetic neuropathy are frequently told their diabetes is "controlled" while the neuropathy progresses because the underlying metabolic driver is inadequately addressed.
Protocol implications: Metabolic optimization is the primary modality for diabetic neuropathy. GLP-1 agonist therapy (semaglutide or tirzepatide) addresses glucose regulation, insulin sensitivity, and inflammation simultaneously. Combined with IV ALA (alpha-lipoic acid) for mitochondrial support and Class IV laser for local nerve stimulation.
2. Peripheral (Idiopathic and Non-Specific) A significant percentage of peripheral neuropathy patients have no identified cause after standard workup. This is labeled "idiopathic." However, idiopathic neuropathy often represents metabolic, nutritional, or inflammatory contributors that standard workups do not fully evaluate.
Protocol implications: Comprehensive lab evaluation at Rebuild Regen goes beyond standard neuropathy workup. B12 status, folate, copper, zinc, MTHFR genetic variant (which affects B12 metabolism), inflammatory markers, thyroid function, and celiac antibodies are evaluated as contributors. Many "idiopathic" patients have a treatable nutritional or inflammatory driver discovered at this level of evaluation.
3. Compressive (Physical Entrapment) Nerve compression from spinal disc herniation, stenosis, or peripheral nerve entrapment (carpal tunnel, tarsal tunnel, peroneal nerve entrapment) produces nerve damage that presents as neuropathy symptoms in the distribution of the compressed nerve. Lumbar spinal stenosis is a particularly important compressive cause in older patients who present with lower extremity neuropathy symptoms.
Protocol implications: Mechanical decompression via Antalgic-Trac spinal decompression or Knee on Trac is the primary treatment for compressive neuropathy. Laser and IV nutritional support address the inflammatory and nutritional components, but decompression of the physical entrapment is the priority modality.
4. Chemotherapy-Induced Peripheral Neuropathy (CIPN) Chemotherapy agents including taxanes (paclitaxel, docetaxel), platinum compounds (cisplatin, oxaliplatin), and vincristine produce direct axonal toxicity. CIPN affects 30 to 40 percent of cancer patients receiving these agents and often persists after chemotherapy ends.
Protocol implications: CIPN involves a combination of direct axonal damage and secondary ischemic changes. IV nutritional support (B12, ALA, NAD+) addresses mitochondrial dysfunction and oxidative stress from axonal damage. Class IV laser therapy supports local tissue perfusion and nerve regeneration signaling. CIPN is one of the conditions where IV DayZero™ stem cell therapy may be considered as an adjunct for patients with significant persistent CIPN, as MSC-derived neurotrophic factors support nerve repair processes.
5. Hormonal (HRT/TRT-Responsive) Hypothyroidism produces peripheral neuropathy through multiple mechanisms including fluid accumulation that compresses nerves, reduced nerve conduction velocity, and impaired mitochondrial function. Testosterone deficiency in men and estrogen deficiency in women both affect nerve health and can produce or worsen neuropathic symptoms.
Protocol implications: Hormonal correction is the primary treatment for hormone-driven neuropathy. Thyroid replacement for hypothyroidism, TRT for testosterone-deficient men, HRT for estrogen-deficient women. Without correcting the hormonal driver, other neuropathy treatments produce incomplete responses.
Types of Neuropathy: Diabetic, Peripheral, Chemotherapy-Induced, Small Fiber, Idiopathic, and Compressive
Understanding the specific type of neuropathy is essential to selecting the right modality combination.
Diabetic Peripheral Neuropathy (DPN)
The most common neuropathy type. Affects primarily the distal extremities in a "stocking and glove" distribution, beginning in the feet and ascending. Symptoms include burning pain, tingling, numbness, and loss of protective sensation. Loss of protective sensation in the feet creates significant fall risk and wound healing complications. Early identification and metabolic control are the primary prevention strategies; the Rebuild Protocol addresses both active symptoms and the underlying metabolic driver.
Peripheral Neuropathy (Non-Diabetic)
A broad category including neuropathy from autoimmune causes (Guillain-Barre syndrome, CIDP, lupus-associated), infectious causes (Lyme disease, HIV, shingles), toxic causes (alcohol, heavy metals, certain medications), nutritional deficiencies (B12, B1, B6), and genetic causes (Charcot-Marie-Tooth disease). Each of these has distinct treatment implications. The comprehensive diagnostic workup at Rebuild Regen identifies which category applies.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Directly toxic to peripheral nerve axons via oxidative stress and mitochondrial disruption. CIPN often affects both sensory and motor nerves, producing numbness, tingling, burning, and in severe cases weakness in the hands and feet. CIPN is distinct from diabetic neuropathy in mechanism but shares the feature of irreversibility in severe cases when treatment is delayed. Early intervention during or immediately after chemotherapy produces better outcomes than late treatment.
Small Fiber Neuropathy (SFN)
Affects the small, unmyelinated nerve fibers responsible for pain and temperature sensation. Standard nerve conduction studies (NCS) test large fiber function and are NORMAL in small fiber neuropathy. SFN is diagnosed by skin punch biopsy measuring intraepidermal nerve fiber density (IENFD) or autonomic testing. Many patients with SFN are told their nerve studies are normal and their symptoms are therefore not neuropathy, when in fact the standard test is simply the wrong test for their condition.
Symptoms of SFN: burning pain, allodynia (pain from light touch), temperature hypersensitivity, autonomic symptoms (sweating abnormalities, bowel and bladder changes, heart rate variability changes). SFN is associated with pre-diabetes, autoimmune conditions, sarcoidosis, celiac disease, and genetic mutations (SCN9A and others).
Protocol implications: IV ALA is the strongest evidence-based intervention for SFN. Class IV laser supports local nerve fiber density recovery in some studies. The metabolic and autoimmune driver workup is essential.
Idiopathic Neuropathy
Neuropathy with no identified cause after standard evaluation. The Rebuild Regen approach goes beyond standard evaluation to evaluate B12 pathway genetics, inflammatory markers, and hormonal contributors. Some idiopathic neuropathy patients have identifiable and treatable contributors that standard workups miss.
Compressive Neuropathy
Physical entrapment or compression of nerve tissue at specific anatomical sites. Lumbar spinal stenosis and disc herniation are common compressive causes of lower extremity neuropathy. Cervical disc disease produces upper extremity neuropathy. Peripheral entrapment (carpal tunnel, cubital tunnel, tarsal tunnel) produces site-specific distributions. The symptom distribution helps localize the compression; imaging confirms it.
The Rebuild Neuropathy Protocol™: 6 Modalities Explained
The Rebuild Neuropathy Protocol™ is the named methodology at Rebuild Regen Medical Clinic for addressing peripheral neuropathy through a diagnosis-first, multi-modal approach. No single modality addresses every mechanism of nerve damage. The protocol selects from six available modalities based on the root cause and the individual patient's presentation.
The 6 modalities are:
- LightForce® XLi Class IV Laser Therapy (photobiomodulation)
- Chattanooga Intelect RPW 2 Shockwave Therapy (blood flow restoration)
- IV Infusions (B12, ALA, NAD+)
- Hormonal Correction (HRT/TRT)
- Metabolic Optimization (semaglutide, tirzepatide, peptides)
- Mechanical Decompression (Knee on Trac, Antalgic-Trac®)
Most patients receive 2 to 4 modalities in combination based on their root cause diagnosis. The protocol is not a fixed program. It is a clinical framework that Elizabeth Celestin applies based on each patient's specific situation.
Modality 1: LightForce® XLi Class IV Laser (Photobiomodulation)
The LightForce® XLi Class IV Therapy Laser delivers photobiomodulation, the use of specific light wavelengths to trigger cellular responses in nerve and surrounding tissue, as the primary non-invasive neuroregenerative tool in the Rebuild Neuropathy Protocol™.
The Photobiomodulation Mechanism
Class IV laser therapy at therapeutic wavelengths (typically 810 to 1064 nm) penetrates deeply into tissue. At the cellular level, the photons are absorbed by cytochrome c oxidase in the mitochondrial electron transport chain. This interaction:
Increases ATP production: Enhanced mitochondrial function directly supports nerve cell energy metabolism. Peripheral nerve cells are metabolically demanding. In neuropathic conditions where mitochondrial dysfunction is a driver, laser-stimulated ATP production provides the energy substrate for repair processes.
Increases nitric oxide production: Photobiomodulation releases nitric oxide (NO) from its bound state in cytochrome c oxidase and nitrosyl hemoglobin. Free NO is a potent vasodilator and neuroprotective signaling molecule. In the neuropathic context, increased NO improves blood flow to ischemic nerve tissue.
Reduces neuroinflammation: Laser therapy decreases pro-inflammatory cytokine production at the treatment site. The anti-inflammatory effect at the nerve level reduces the ongoing inflammatory damage that drives neuropathy progression.
Stimulates axonal regeneration: Evidence from animal and human studies supports photobiomodulation's ability to accelerate nerve fiber regeneration and increase intraepidermal nerve fiber density in small fiber neuropathy.
Why Class IV Matters
The distinction between Class III (low-level laser therapy/LLLT) and Class IV is primarily about power and tissue penetration. Class III devices typically operate below 500 mW. The LightForce® XLi operates at up to 25 watts. Higher power means deeper tissue penetration, which is essential for reaching nerves in the feet and lower legs rather than just the superficial skin layers.
At Rebuild Regen, the LightForce® XLi is used for lower extremity neuropathy (bilateral lower leg and foot protocols), upper extremity neuropathy, and focal nerve applications where the laser delivers a concentrated therapeutic dose to the nerve distribution in question.
Typical laser protocol for neuropathy:
- 2 to 3 sessions per week during the active treatment phase (typically 6 to 12 weeks)
- 5 to 15 minutes per session depending on the treatment area and power setting
- Each session delivers a specific joule dose calculated for the target tissue depth and area
Patients report warmth during treatment and often begin noticing symptom improvement after 4 to 8 sessions.
Modality 2: Chattanooga Intelect RPW 2 Shockwave Therapy
The Chattanooga Intelect RPW 2 delivers radial pressure wave (shockwave) therapy that restores blood flow, stimulates tissue remodeling, and addresses the vascular component of peripheral neuropathy through mechanical acoustic energy.
How Shockwave Addresses Neuropathy
Peripheral nerve health is inseparable from peripheral vascular health. Nerves are supplied by small blood vessels (vasa nervorum) that deliver oxygen and nutrients. In diabetic neuropathy, these vessels are damaged by hyperglycemia. In peripheral artery disease-associated neuropathy, reduced arterial flow starves nerve tissue. In any neuropathy with a significant ischemic component, restoring blood flow is as important as addressing the nerve itself.
The Chattanooga Intelect RPW 2 produces mechanical pressure waves that penetrate soft tissue at 1 to 10 cm depth depending on frequency and probe settings. In neuropathy treatment, the relevant mechanisms include:
Angiogenesis stimulation: Radial pressure waves stimulate VEGF (vascular endothelial growth factor) release, promoting the formation of new small blood vessels in treated tissue. In the lower legs and feet, this neovascularization can restore nutrient delivery to nerve tissue that has been chronically ischemic.
Reduction of calcific deposits: In some forms of neuropathy associated with vascular calcification, shockwave therapy physically disrupts and remodels calcified deposits that restrict blood flow to nerve-supplying vessels.
Tissue remodeling and fibrosis reduction: Chronic neuropathy is associated with perivascular fibrosis (scar tissue formation around blood vessels) that reduces vessel flexibility and flow. Shockwave's mechanical effect breaks down fibrotic tissue, improving vessel compliance.
Mast cell activation and growth factor release: The mechanical stimulus of shockwave triggers local mast cell degranulation, releasing growth factors including TGF-beta and HGF that support tissue regeneration.
Clinical Application for Neuropathy
For lower extremity neuropathy, the Chattanooga Intelect RPW 2 is applied to the calf musculature, plantar fascia, and the dorsal foot. Sessions run 10 to 15 minutes per area. Pressure settings are adjusted based on patient tolerance, typically starting lower and increasing over the course of the treatment series.
Shockwave for neuropathy is most effective when the vascular component is a significant contributor, which includes:
- Diabetic peripheral neuropathy with microangiopathy
- Peripheral artery disease-associated neuropathy
- CIPN with documented ischemic changes
- Idiopathic neuropathy where circulation testing shows reduced perfusion
It is frequently combined with Class IV laser therapy in the same treatment session, as photobiomodulation and shockwave address complementary aspects of the neuropathy mechanism simultaneously.
Modality 3: IV Infusions (B12, ALA, NAD+)
Intravenous nutritional therapy delivers three key compounds directly into the bloodstream, bypassing the absorption limitations of oral supplementation to achieve therapeutic concentrations at the nerve level.
Methylcobalamin (Vitamin B12)
Vitamin B12 deficiency is one of the most common and reversible causes of peripheral neuropathy. Methylcobalamin, the neurologically active form of B12, is essential for:
- Myelin synthesis and myelin sheath maintenance
- Axonal transport and repair
- Methionine cycle function (affects nerve methylation)
- Reduction of homocysteine (elevated homocysteine is directly neurotoxic)
B12 deficiency is common and often missed because:
- Standard reference ranges are too low (many neurologically symptomatic patients have "normal" serum B12 at 200 to 400 pg/mL when functional deficiency begins below 500 to 600 pg/mL)
- Metformin (widely used for diabetes, the most common neuropathy cause) depletes B12 via impaired absorption
- Proton pump inhibitors (PPIs) reduce B12 absorption
- MTHFR genetic variants impair B12 metabolism even with adequate intake
IV methylcobalamin bypasses all absorption limitations and delivers the neurologically active form directly. Doses for neuropathy IV protocols are substantially higher than oral supplement levels.
Alpha-Lipoic Acid (ALA)
Alpha-lipoic acid is a potent mitochondrial antioxidant with the strongest evidence base of any nutritional compound in peripheral neuropathy treatment. The SYDNEY and SYDNEY 2 trials demonstrated significant improvement in neuropathy symptoms with IV ALA versus placebo in diabetic peripheral neuropathy.
Mechanisms of ALA in neuropathy:
- Regenerates endogenous antioxidants (glutathione, vitamins C and E) that are depleted by oxidative stress in neuropathic tissue
- Directly scavenges free radicals produced by mitochondrial dysfunction in damaged nerve cells
- Improves endoneural blood flow via NO-mediated vasodilation
- Reduces AGE formation that drives diabetic nerve damage
- Crosses the blood-brain barrier (relevant for central neuropathic pain components)
IV ALA produces substantially higher peak plasma concentrations than oral ALA, and the evidence for IV administration is stronger than for oral. The typical IV dose is 600 to 1,200 mg per infusion, 2 to 3 times weekly during the active treatment phase.
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ is a critical coenzyme in every cell, central to mitochondrial energy production (ATP synthesis via the electron transport chain) and the repair activity of PARP and sirtuin enzymes, which detect and repair DNA damage.
In neuropathy, NAD+ is relevant because:
- Peripheral nerve cells are among the most metabolically demanding cells in the body. Mitochondrial dysfunction in neuropathy is directly linked to NAD+ depletion.
- SIRT1 and SIRT3 (NAD+-dependent sirtuins) regulate mitochondrial biogenesis and axonal health. When NAD+ is insufficient, these protective pathways are suppressed.
- Chemotherapy-induced neuropathy involves PARP activation consuming NAD+ in response to DNA damage, depleting the cell's repair substrate.
IV NAD+ infusions replenish the cellular NAD+ pool, supporting mitochondrial function, nerve repair enzyme activity, and cellular energy production in neuropathic tissue.
Combined IV protocol: At Rebuild Regen, B12, ALA, and NAD+ are typically combined in a single IV session, running 60 to 90 minutes. This combination addresses three distinct but complementary aspects of nerve cell metabolism simultaneously.
Modality 4: Hormonal Correction (HRT/TRT for Hormone-Driven Neuropathy)
Hormonal correction is the primary modality for neuropathy patients whose root cause is hormonal. This is the most overlooked contributor to peripheral neuropathy in conventional neurology practice.
Thyroid and Neuropathy
Hypothyroidism is a direct cause of peripheral neuropathy via multiple mechanisms:
- Reduced nerve conduction velocity (thyroid hormone affects myelin synthesis and axonal transport)
- Fluid retention that compresses peripheral nerves at entrapment sites
- Reduced blood flow to peripheral nerve tissue
- Carpal tunnel syndrome as a classic hypothyroid manifestation
TSH and free thyroid hormone levels are part of the Rebuild Regen neuropathy evaluation. Patients on thyroid replacement who are inadequately dosed (TSH above 2.5 mIU/L in symptomatic patients) often have correctable neuropathy that standard neuropathy treatment cannot resolve while the thyroid remains undertreated.
Testosterone Deficiency and Male Neuropathy
Testosterone plays a direct role in peripheral nerve health. Androgen receptors are present on Schwann cells (the cells that produce myelin in the peripheral nervous system). Testosterone supports Schwann cell function and myelin maintenance. Men with hypogonadism (low testosterone) have documented reductions in nerve conduction velocity and increased neuropathy risk.
Additionally, testosterone deficiency is associated with metabolic syndrome and impaired glucose regulation, which drives the diabetic neuropathy pathway as a secondary mechanism.
TRT as part of the Rebuild Neuropathy Protocol for testosterone-deficient men addresses both the direct nerve health mechanism and the metabolic driver simultaneously.
Estrogen and Female Neuropathy
Estrogen exerts neuroprotective effects via anti-inflammatory signaling, maintenance of small fiber nerve density, and modulation of pain sensitivity. Menopausal estrogen deficiency is associated with increased neuropathic pain sensitivity and small fiber neuropathy risk. Women presenting with neuropathic symptoms at menopause onset or in the perimenopausal period receive a full hormone evaluation as part of the neuropathy workup.
Modality 5: Metabolic Optimization (Semaglutide, Tirzepatide, Peptides)
Metabolic optimization is the primary modality for diabetic and pre-diabetic neuropathy, and an important supporting modality for neuropathy driven by metabolic syndrome, obesity-associated inflammation, or insulin resistance.
GLP-1 Agonists for Diabetic Neuropathy
Semaglutide and tirzepatide address the root cause of diabetic peripheral neuropathy by improving glucose regulation, reducing insulin resistance, and directly reducing neuroinflammation. Beyond glucose control, GLP-1 receptors are expressed in peripheral nerve tissue, and GLP-1 agonist activity has neuroprotective effects that are independent of glucose lowering.
Mechanisms in neuropathy:
- Reduction in AGE formation via glucose normalization
- Anti-inflammatory effects in nerve tissue via GLP-1 receptor signaling
- Improvement in endothelial function, increasing blood flow to vasa nervorum
- Weight reduction, which improves insulin sensitivity and reduces the metabolic driver of continued nerve damage
For patients with pre-diabetic neuropathy (HbA1c 5.7 to 6.4 percent), GLP-1 agonist initiation as part of the Rebuild Protocol addresses the glucose driver before frank diabetes develops, which is the most effective point of metabolic intervention.
BPC-157 and Nerve Repair
BPC-157 is incorporated into neuropathy protocols for patients where the repair signaling mechanism is relevant. Its VEGF-stimulating and NO-modulating properties support nerve blood supply restoration. In CIPN, BPC-157's cytoprotective and repair-signaling mechanisms are used alongside IV nutritional support and laser therapy.
Modality 6: Mechanical Decompression (Knee on Trac, Antalgic-Trac®)
Mechanical decompression is the primary modality for compressive neuropathy and the essential first step when physical nerve entrapment is the root cause.
Antalgic-Trac® Spinal Decompression
Spinal decompression using the Antalgic-Trac® system is applied for neuropathy caused by lumbar or cervical disc compression. By applying a controlled, sustained distraction force to the spine, the Antalgic-Trac® reduces intradiscal pressure, increases foraminal space, and reduces the compressive force on affected nerve roots.
Lumbar spinal stenosis producing lower extremity neuropathy and cervical disc herniation producing upper extremity neuropathy are the primary indications for spinal decompression within the neuropathy protocol. Decompression does not reverse advanced disc degeneration, but it reduces the compressive load that is actively injuring the nerve root.
Knee on Trac Knee Decompression
For neuropathy associated with peroneal nerve compression at the knee, or concurrent knee joint pathology that contributes to lower extremity symptoms, the Knee on Trac device provides distraction and decompression of the knee joint. This is a supporting modality for lower extremity neuropathy patients with concurrent knee OA or post-surgical knee changes.
Combination with Other Modalities
Mechanical decompression removes the physical source of nerve compression. But compressed nerves often have secondary inflammatory changes and ischemic damage that persist even after the compressive force is reduced. For this reason, spinal decompression protocols are combined with Class IV laser therapy and IV nutritional support to address the inflammatory and nutritional components of the nerve damage simultaneously.
How Most Neuropathy Clinics Fail Their Patients
Most neuropathy clinics charge $10,000 to $20,000 for a rigid, one-size-fits-all program. The Rebuild Neuropathy Protocol™ is different. We diagnose your root cause first.
This is not a marketing distinction. It is a clinical one that has direct consequences for outcomes.
Here is the standard model that most neuropathy clinics operate on:
Step 1: Patient presents with numbness and burning in feet. Step 2: Clinic prescribes a fixed multi-week program of laser therapy, e-stim, and nutritional supplements. Step 3: Patient pays $12,000 to $18,000 upfront for a set number of sessions. Step 4: Patient completes the program. Some improve. Many do not. Step 5: For those who do not improve, the reason the program failed is never investigated.
Why does this model fail? Because the patient with diabetic neuropathy has a different root cause than the patient with B12 deficiency neuropathy, who has a different root cause than the patient with lumbar stenosis-driven neuropathy, who has a different root cause than the patient with hormonal-driven neuropathy. Running every patient through the same protocol, regardless of root cause, is the definition of treating symptoms rather than disease.
The Rebuild Neuropathy Protocol™ begins with the diagnostic question. Labs are drawn. The symptom distribution is mapped. Imaging is reviewed. Hormonal status is evaluated. Only after the root cause category is established does the treatment selection begin.
A patient with hormonal neuropathy gets hormonal correction as the priority treatment. A patient with compressive neuropathy gets spinal decompression. A patient with diabetic neuropathy gets metabolic optimization with GLP-1 therapy combined with IV ALA and Class IV laser. A patient with CIPN gets IV B12, ALA, NAD+, and photobiomodulation.
And none of them pay $12,000 upfront for a program designed for a different patient.
Who Is a Candidate for the Rebuild Neuropathy Protocol™
The Rebuild Neuropathy Protocol™ is appropriate for patients across all neuropathy types and stages, with specific expectations calibrated to where in the neuropathy progression the patient presents.
Strong candidates:
- Patients with diagnosed peripheral neuropathy who have not achieved adequate symptom control on gabapentin, pregabalin, or other medications
- Patients with diabetic neuropathy who want to address the metabolic driver alongside symptom management
- Patients with CIPN who finished chemotherapy and need active nerve repair support
- Patients with suspected hormonal or nutritional contributors to neuropathy who have not been worked up comprehensively
- Patients with small fiber neuropathy who have been told their nerve studies are normal
- Patients who have failed other neuropathy treatment programs
What the evaluation includes:
- Comprehensive neuropathy history (symptom distribution, onset, duration, prior treatments, medications)
- Physical examination including sensation testing, reflexes, and balance
- Targeted lab panel including B12, HbA1c, thyroid, inflammatory markers, and hormonal evaluation
- Review of any prior nerve conduction studies and imaging
- Root cause categorization and protocol design
What to bring to the consultation:
- List of all current medications (especially metformin, PPIs, statins, which each have neuropathy-relevant interactions)
- Prior nerve study results (NCS/EMG) if available
- MRI results if relevant to compressive component evaluation
- Prior treatment history and response
What to Expect: Evaluation Through Treatment
Week 1: Evaluation and Root Cause Identification
The initial consultation with Elizabeth Celestin covers the full neuropathy history and initiates the diagnostic lab panel. If prior imaging exists, it is reviewed. If spinal pathology is suspected as a compressive contributor, imaging may be ordered.
Lab results are reviewed at a second appointment within 1 to 2 weeks. The root cause category is established, and the protocol modalities are selected and explained to the patient. Pricing is transparent at this point.
Weeks 2 to 4: Protocol Initiation
Active treatment begins based on the root cause-selected modalities. For most patients, this means:
- 2 to 3 laser sessions per week
- Weekly IV infusion (B12/ALA/NAD+) if indicated
- Any hormonal protocol initiation if indicated (with appropriate baseline labs)
- Metabolic peptide initiation if indicated
- Spinal decompression sessions if indicated (typically 3 per week initially)
Weeks 4 to 12: Active Treatment Phase
The core treatment phase. Most patients complete the initial active treatment series over 6 to 12 weeks. The specific duration depends on severity and root cause.
Response assessment at week 4 to 6: the patient and Elizabeth Celestin evaluate symptom response and adjust the protocol as needed. Patients with inadequate early response may have root cause reassessment or protocol additions.
Months 3 to 6: Consolidation and Maintenance
After the initial series, the frequency of active treatment sessions decreases. Patients transition to maintenance: monthly or quarterly IV infusions, periodic laser booster sessions, continued metabolic or hormonal management. Labs are repeated at 3 months.
Results and Realistic Expectations
Neuropathy treatment outcomes depend critically on the type and severity of neuropathy, the root cause, and how early in the disease progression treatment is initiated.
What is realistic:
For diabetic neuropathy with active metabolic optimization: Significant reduction in burning and tingling is the most common early response. Complete resolution of numbness is less predictable and depends on the degree of established axonal loss. Patients who begin treatment early in the diabetic neuropathy progression see better outcomes than those with advanced axonal degeneration.
For B12-deficiency neuropathy: B12 correction produces some of the most dramatic neuropathy reversals seen in clinical practice. Patients with B12 deficiency neuropathy who begin IV B12 repletion at 6 to 12 months report significant recovery over 3 to 6 months of treatment. Established axonal damage is slower to reverse than early-stage deficiency neuropathy.
For compressive neuropathy: Relief is often faster than other types when the compressive force is adequately reduced. Patients with lumbar stenosis neuropathy often notice improvement in lower extremity symptoms within 2 to 4 weeks of consistent spinal decompression.
For CIPN: Results are more variable. The extent of axotoxic damage from chemotherapy agents limits complete recovery. Reduction in pain, burning, and tingling is achievable for most patients. Sensory restoration in severely affected areas is less predictable.
Realistic expectations across neuropathy types:
- Pain (burning, shooting, tingling): responds earlier, within 4 to 8 weeks in most patients
- Numbness: responds more slowly, often requiring 3 to 6 months of consistent treatment
- Motor function (weakness, balance): improves only when viable motor neurons remain; advanced motor neuropathy has limited reversibility
- No protocol guarantees complete resolution. Partial improvement in quality of life is a meaningful and achievable goal for patients who have been living with progressive neuropathy.
Costs: What the Protocol Includes
The Rebuild Neuropathy Protocol™ is priced based on the modalities selected for each individual patient, not as a fixed program.
Most neuropathy programs charge $10,000 to $20,000 regardless of what the patient actually needs. At Rebuild Regen, the protocol is assembled from the modalities appropriate to the root cause, and priced accordingly.
General cost structure:
- Initial evaluation consultation: first visit
- Lab panel: ordered through standard lab services
- Laser therapy sessions: per session or package rates
- IV infusion sessions: per session
- Spinal or joint decompression sessions: per session
- Hormonal protocol (HRT/TRT): ongoing management fee
- Metabolic peptides (semaglutide, tirzepatide): monthly medication plus monitoring
Transparent pricing for each component is provided at the consultation. Patients know exactly what they are paying for and why.
Some components of the evaluation (labs with appropriate diagnostic codes) may be partially covered by insurance. The active treatment modalities are generally self-pay. Medical financing is available.
Is the Rebuild Neuropathy Protocol™ Right for Your Type of Neuropathy?
The Rebuild Neuropathy Protocol™ addresses neuropathy through root cause identification and multi-modal treatment. Whether it is the right fit depends on whether the patient's root cause falls within the categories the clinic addresses and whether the patient is at a stage where conservative intervention can produce meaningful benefit.
The patients who benefit most are those who have been managing symptoms without addressing the cause, patients with identifiable metabolic, hormonal, nutritional, or compressive contributors that have not been aggressively treated, and patients who are motivated to engage with a comprehensive protocol rather than a single-modality approach.
The honest evaluation at consultation identifies patients for whom the protocol is the right fit and those for whom a referral to neurology, pain management, or surgery is the more appropriate next step.
Frequently Asked Questions
What is the Rebuild Neuropathy Protocol™?
The Rebuild Neuropathy Protocol™ is the named clinical methodology at Rebuild Regen Medical Clinic for treating peripheral neuropathy. It begins with root cause diagnosis rather than immediate treatment, and applies up to 6 modalities, including LightForce® XLi Class IV laser, Chattanooga Intelect RPW 2 shockwave, IV infusions (B12, ALA, NAD+), hormonal correction (HRT/TRT), metabolic optimization (GLP-1 agonists, peptides), and mechanical decompression, based on each patient's identified root cause. No two protocols are identical.
How is this different from other neuropathy programs?
Most neuropathy programs apply the same treatment to every patient regardless of root cause. The Rebuild Neuropathy Protocol™ begins with diagnosis. A patient with diabetic neuropathy receives metabolic optimization alongside laser and IV nutritional support. A patient with compressive neuropathy receives spinal decompression. A patient with hormonal neuropathy receives HRT or TRT. The root cause drives the modality selection. Additionally, Rebuild Regen does not charge a $10,000 to $20,000 upfront program fee; treatment is priced by the modalities each patient actually needs.
Does neuropathy treatment work for diabetic neuropathy specifically?
Diabetic neuropathy responds to the Rebuild Neuropathy Protocol™ across multiple mechanisms. GLP-1 agonist therapy (semaglutide or tirzepatide) addresses the metabolic driver by improving glucose regulation and reducing neuroinflammation. IV alpha-lipoic acid addresses oxidative stress in nerve tissue, with the strongest nutritional evidence base of any compound for DPN. Class IV laser therapy supports local nerve perfusion. The combination addresses three of the four primary mechanisms driving diabetic nerve damage simultaneously.
Can chemotherapy-induced neuropathy be treated?
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the more challenging neuropathy types because of the direct axotoxic damage from chemotherapy agents. The Rebuild Neuropathy Protocol™ addresses CIPN via IV nutritional support (B12 for myelin, ALA for antioxidant, NAD+ for mitochondrial repair), Class IV laser therapy for local tissue perfusion, and in appropriate candidates, IV DayZero™ stem cell therapy for neurotrophic factor support. Results depend on the severity of CIPN and how soon after chemotherapy treatment begins.
What does neuropathy treatment feel like?
Class IV laser therapy produces a warm sensation during treatment. Shockwave therapy produces a tapping or vibrating sensation that some patients find mildly uncomfortable at higher pressures. IV infusion sessions are comfortable, similar to a standard IV drip. Spinal decompression involves a gentle, controlled traction sensation. None of the modalities in the Rebuild Neuropathy Protocol™ involve significant procedural pain.
How many sessions are required?
The number of sessions depends on the root cause, the severity of neuropathy, and the modalities applied. Laser therapy is typically applied 2 to 3 times weekly for 6 to 12 weeks in the active phase. IV infusions run weekly or biweekly during the active treatment phase. Spinal decompression is typically 3 sessions per week for 4 to 8 weeks. Hormonal and metabolic optimization are ongoing. The treating provider gives a session estimate at the consultation after root cause evaluation.
Does insurance cover neuropathy treatment?
Standard health insurance covers the diagnostic workup (labs, nerve studies, imaging) and may cover components of the treatment that correspond to covered diagnosis codes. The advanced modalities in the Rebuild Neuropathy Protocol™ (Class IV laser, IV nutritional infusions, shockwave) are generally self-pay. Hormonal protocols and metabolic peptides (including GLP-1 agonists) have variable insurance coverage depending on the patient's insurance plan and documented diagnoses. Medical financing is available.
Will I need medications alongside the protocol?
The Rebuild Neuropathy Protocol™ is designed to work alongside any current neuropathy medications. Elizabeth Celestin reviews all current medications at the consultation. Some patients find that as the protocol produces symptom improvement, their physician is able to reduce gabapentin or pregabalin doses. The protocol does not require patients to discontinue any medications. Medication decisions are made with the patient's prescribing physician.
Can small fiber neuropathy be treated?
Small fiber neuropathy responds to treatment that addresses the intraepidermal nerve fiber damage, including IV ALA (which has the strongest evidence base in SFN), Class IV laser therapy, and treatment of identified root causes (pre-diabetes, autoimmune drivers). The diagnostic workup includes evaluation for all common SFN root causes. Normal nerve conduction studies do not rule out SFN; skin punch biopsy is the standard diagnostic test for SFN.
Is neuropathy reversible?
The degree of reversibility depends on whether viable nerve fibers remain. Peripheral nerves have the capacity for regeneration (unlike central nervous system neurons). When axonal damage is present but nerve cells are still alive, regeneration is possible with appropriate treatment and time. When axons are completely degenerated or nerve cells have died, reversal is limited. The general principle is that early intervention, before irreversible structural damage is established, produces the best outcomes. Partial improvement in pain, function, and quality of life is achievable in most cases even when complete reversal is not.
What labs are ordered for the neuropathy evaluation?
The Rebuild Regen neuropathy lab panel includes: HbA1c and fasting glucose (metabolic driver); vitamin B12 (serum and methylmalonic acid if B12 is borderline); folate; thyroid panel (TSH, free T3, free T4); complete hormonal panel (testosterone, estradiol, DHEA); inflammatory markers (CRP, ESR); homocysteine (elevated with B12 deficiency); anti-nuclear antibody and ESR (autoimmune screening); comprehensive metabolic panel; CBC; and if celiac is suspected, celiac antibodies.
How long before neuropathy pain improves?
Pain (burning, tingling, shooting sensations) is typically the first symptom to respond to neuropathy treatment. Most patients report initial reduction in pain intensity within 4 to 8 sessions of Class IV laser therapy combined with IV nutritional support. Numbness and sensory deficits take longer, often 8 to 16 weeks or more depending on severity. The treating provider sets realistic expectations at consultation based on the specific type and severity of neuropathy.
When Neuropathy Has Progressed Beyond Conservative Intervention
The Rebuild Neuropathy Protocol™ is a conservative, non-surgical, non-opioid approach to peripheral neuropathy. There are stages of neuropathy progression where conservative intervention reaches the limits of its utility, and honest evaluation requires acknowledging them.
Complete axonal degeneration with confirmed nerve loss: When nerve conduction studies show absent responses (not just slowed, but absent), the axons in that nerve distribution have been lost. Regeneration from absent axons is not possible. At this stage, the realistic goal shifts from nerve recovery to symptom management, fall prevention, and slowing any progression in remaining viable nerve tissue.
Spinal pathology requiring surgical decompression: When spinal stenosis or disc herniation has produced severe, progressive, or bilateral neuropathy with motor involvement (weakness, bowel/bladder dysfunction), surgical decompression is the appropriate intervention. Mechanical decompression via Antalgic-Trac can support patients with moderate compressive neuropathy, but severe structural compression with progressive deficits requires neurosurgical evaluation. The Rebuild Regen consultation is transparent about when this referral is the right next step.
Advanced diabetic neuropathy with established motor loss: When diabetic neuropathy has progressed to include foot drop, significant motor weakness, or complete loss of protective sensation with active ulceration, the management complexity requires multidisciplinary care including podiatry, wound care, and vascular surgery input alongside the metabolic and supportive care the Rebuild Protocol provides.
Patients who have exhausted all conservative options: Some patients with advanced neuropathy have tried everything. At that point, the honest conversation includes what the realistic goals of the protocol are (pain reduction, functional improvement, slowing progression) rather than reversal, and whether those goals are meaningful enough to justify the treatment investment.
Elizabeth Celestin does not fill false hope. She does provide honest assessment of what the protocol can and cannot achieve for each patient's specific situation.
Schedule a consultation: (954) 953-4208 | Rebuild Regen Medical Clinic, 3320 N Federal Hwy #101, Lighthouse Point, FL 33064.
Ready to start your recovery?
Schedule a consultation at Rebuild Regen Medical Clinic in Lighthouse Point, FL.